Christin Melton

New evidence presented at the annual meeting of the Society of Gynecologic Oncologists suggests that Gardasil, a vaccine that prevents cervical cancer, also reduces the likelihood of recurrence after surgery by 40%.

Results of a phase III multicenter, open-label study demonstrated that first-line treatment with a combination of cetuximab and a taxane/carboplatin (TC)significantly approved the overall response rate (ORR)and led to slight improvement in overall survival (OS). The study did not meet its primary endpoint of progression-free survival (PFS) as assessed by an independent radiologic review committee (IRCC).

The National Cancer Institute says 15% to 25% of patients with cancer suffer depression. Others suffer from varying levels of stress and anxiety.

Shirley Sampson and colleagues have been working with developers to optimize EHR systems for use with their patients.

ONS released its spring catalog of publications at the annual meeting.

Guidelines have been developed to reduce the number of bloodstream infections in the oncology unit.

Laughter has long been rumored to have healing properties, and now a team of researchers has put that rumor to the test.

The need to eliminate the trial-and-error approach to vein hunting inspired the creation of VeinViewer in 2006.

Getting patients to adhere to their prescribed treatment is becoming a growing concern.

Paula Trahan Rieger, RN, MSN, CAE, FAAN, is the CEO of ONS and has received numerous awards throughout a storied career.

The enactment of federal healthcare reform following a protracted, confrontational debate has left Americans bewildered and wondering, "What happens now?" Since you may soon be inundated with patient's questions, and might have a few of your own, OBTN cuts through the rhetoric, dissects the legislation, and tells you everything you need to know about the historic law and how it may affect your practice.

In March, we published data from the Lysosomal Disease Network WORLD Symposium on new treatment options being studied for type 1 Gaucher disease.

At the National Comprehensive Cancer Network (NCCN) annual meeting, Paul F. Engstrom, MD, Fox Chase Cancer Center, reviewed the recent changes to NCCN guidelines for colon and rectal cancer, released as v.2.2010.

For the first time, scientists have constructed a complete genetic map for two types of cancer: small cell lung cancer and malignant melanoma.

In the April issue of Hepatology, researchers from the University of Alberta in Edmonton, Canada, reported that administering sirolimus (Rapamune)after liver transplantation in patients with nonresectable hepatocellular carcinoma (HCC) significantly increased survival rates.

We interview hematologist Neal Weinreb, MD, director of the University Research Foundation for Lysosomal Storage Diseases and a researcher involved in studying Gaucher disease for more than 3 decades. Dr Weinreb talks about the risks of cancer in patients with type 1 Gaucher disease and why hematologists and oncologists need to know about this rare inherited disorder.

Three presentations at the recent Third Annual Interdisciplinary Prostate Cancer Congress in New York are reviewed. Urologist Leonard Gomella, MD, addresses truths and myths about prostate cancer prevention;Daniel P. Petrylak, MD, discusses the timely topic of immunotherapy; and E. David Crawford, MD, talks about screening controversies.

In data presented at the 2nd European Lung Cancer Conference, a team of investigators said adding ifosfamide to a combination regimen of cisplatin plus etoposide demonstrated strong activity and tolerability in patients with small cell lung cancer (SCLC).

Being able to predict which women diagnosed with ductal carcinoma in situ (DCIS) are likely to develop subsequent invasive breast cancer could prevent a lot of unnecessary treatment, said researchers from the University of California San Francisco (UCSF).

Kantar Health Research recently conducted an Internet survey of approximately 250 oncologists from the United States, France, Germany, Italy,Spain, and the United Kingdom. Using a proprietary scoring system Kantar Health calls the TRI*M Index, the research firm assessed relationships between physicians and pharmaceutical company representatives.

The American Society of Clinical Oncology (ASCO)and the College of American Pathologists (CAP) jointly released guidelines designed to improve the accuracy and usefulness of immunohistochemical (IHC) testing for estrogen receptor (ER) and progesterone receptor (PgR) status in breast cancer tumors after convening a panel of international experts to study the issue.

Oncology & Biotech News is now united with the experienced publishing, editorial, and creative staff of Oncology Net Guide and OncNurse under the Oncology Specialty Group umbrella, which also includes our newest publication, Contemporary Oncology.

Being able to predict which women diagnosed with ductal carcinoma in situ (DCIS) are likely to develop subsequent invasive breast cancer could prevent a lot of unnecessary treatment, said researchers from the University of California San Francisco (UCSF).

In data presented at the 2nd European Lung Cancer Conference, a team of investigators said adding ifosfamide to a combination regimen of cisplatin plus etoposide demonstrated strong activity and tolerability in patients with small cell lung cancer (SCLC).

In a presentation at the Third Annual Interdisciplinary Prostate Cancer Congress (IPCC), Howard M. Sandler, MD, MS, a Ronald H. Bloom Family Chair in Cancer Therapeutics and professor and chair of the Department of Radiation Oncology at Cedars Sinai Medical Center in Los Angeles,

In the April issue of Hepatology, researchers from the University of Alberta in Edmonton, Canada, reported that administering sirolimus (Rapamune) after liver transplantation in patients with nonresectable hepatocellular carcinoma (HCC) significantly increased survival rates.

A study presented at the 51st American Society of Hematology Meeting and Expedition reported that 5 days of palonosetron (Aloxi) was significantly more effective than ondansetron at preventing delayed chemotherapy-induced nausea and vomiting (CINV) in patients with acute myelogenous leukemia (AML). Both drugs had similar efficacy in preventing acute CINV.

Many cancers increase the risk of other serious events and many treatments have their own risks and adverse effects that must be managed.

Women with uterine cancer who are treated with laparoscopy have a 3-year rate of overall survival similar to that of women who undergo traditional laparotomy.

When adolescents and young adults develop cancer, clinicians contend with an entirely different set of considerations in treatment and follow-up.